Product Labeling Should Add "Expected" Adverse Event Section, Bristol Says
Executive Summary
Bristol-Myers Squibb is proposing the addition of an "expected" adverse events section to product labeling in order to minimize regulatory reporting of events that occur frequently in both drug and control groups, the company said in comments on FDA's AE labeling draft guidance.